Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year FY2025 earnings reported March 3, 2026; full financials in Exhibit 99.1.
Amylyx Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year FY2025 earnings reported March 3, 2026; full financials in Exhibit 99.1
- Results cover period ended December 31, 2025; no key figures disclosed in this filing item
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Amylyx Pharmaceuticals, Inc. 8-K filings
Get the next AMLX 8-K as it lands
Follow AMLX for push alerts, or ask the research agent what this filing means.